This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners & Losers: Gilead

Biotech stocks overall ticked up slightly Thursday, but one notable exception was Cell Genesys (CEGE), which sank 75% to 17 cents on word of a serious clinical setback.

The decline in Cell Genesys came after the company said it terminated a second study on its prostate cancer vaccine GVAX, and said it would cut 75% of its workforce.

Still, Cell Genesys did little to hurt the Nasdaq Biotechnology index, of which it's a component. The index added 3.3%, outperforming the broader market.

The Amex Biotechnology index added 2.1%. Components and biotech bellwethers Amgen (AMGN - Get Report) and Celgene (CELG - Get Report) added 1.6% and 1.5%, respectively.

Celgene (CELG - Get Report) and Acceleron Pharma said they have initiated a midstage trial on an investigational bone loss therapy in patients with multiple myeloma. It will trigger a $5 million milestone payment from Celgene to Acceleron.

Following the close, earnings are expected from Gilead (GILD - Get Report). Analysts surveyed by Thomson Reuters are looking for a profit of 49 cents a share on $1.32 billion in revenue. Gilead shares were up 5.9% ahead of quarterly results.

Elsewhere, Brean Murray and Merriman Curhan Ford initiated coverage on multiple small- to mid-cap health-care stocks.

Brean Murray began coverage on Mentor (MNT) with a hold rating. Shares were off by 1.5% at $15.82.

The firm also picked up coverage on Xtent (XTNT), NuVasive (NUVA - Get Report) and Hansen Medical (HNSN - Get Report) with buy ratings. Xtent shares were up 9.8%, and NuVasive gave up 2.2%. Hansen Medical gained 6.6%.

Meanwhile, Merriman Curhan Ford started Dendreon (DNDN) with a sell rating. The stock was down 1.7%, at $80.06. The firm began coverage on Ariad Pharma (ARIA) with a neutral rating. Shares rose 7.3% to $1.61.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMGN $167.91 0.00%
CELG $118.71 0.00%
GILD $103.70 0.00%
HNSN $0.89 0.00%
NUVA $43.99 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs